All Oncology News

PARP inhibition is quickly becoming a major element of the overall ovarian cancer treatment landscape, as several of these agents are continuing to advance through clinical development.

The combination of nivolumab and ipilimumab led to a high response rate and improved overall survival versus historical controls for patients with pretreated metastatic urothelial carcinoma.

The FDA granted a priority review to a new drug application for midostaurin (PKC412) for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia or advanced systemic mastocytosis.

Nivolumab (Opdivo) may be the only checkpoint inhibitor that is approved by the FDA as a treatment of patients with Hodgkin lymphoma, but other immunotherapies—alone and in combination with other novel agents—are emerging in other indications.

The Committee for Medicinal Products for Human Use has recommended approval of ofatumumab in combination with fludarabine and cyclophosphamide as a treatment for patients with relapsed chronic lymphocytic leukemia.

Brentuximab vedotin (Adcetris) has received an FDA breakthrough therapy designation for the treatment of patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large cell lymphoma following at least 1 prior systemic therapy.

The European Commission has granted an accelerated approval to olaratumab in combination with doxorubicin as a frontline therapy for patients with advanced soft tissue sarcoma, making it the first new therapy for this indication in over 40 years.

As a treatment of patients with advanced ovarian cancer, evidence has shown that neoadjuvant chemotherapy has reduced mortality and improved quality of life. However, oncologists are still challenged at how to deploy this treatment approach in clinical practice.

The FDA has approved nivolumab for patients with metastatic or recurrent squamous cell carcinoma of the head and neck following progression on platinum-based therapy.

Treatment with nivolumab significantly extended overall survival compared with placebo for patients with unresectable, advanced, or recurrent gastric cancer who were refractory or intolerant to standard therapy.

Impactful clinical trial data that have led to approvals of novel agents and regimens over the last few years has led to a significant transformation in the multiple myeloma landscape.

Using combination regimens in an effective manner will likely be a go-to method with immunotherapy in multiple myeloma, in an effort to induce durable responses in patients.

The European Commission approved palbociclib (Ibrance) for use in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor in the frontline setting or combined with fulvestrant after progression on endocrine therapy.

The FDA has approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).

To best treat patients with clear cell renal cell carcinoma, incorporating precision biomarkers into the current nomogram is essential.

Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.

A supplemental new drug application has been submitted to the FDA for the use of regorafenib (Stivarga) as a second-line treatment for patients with unresectable hepatocellular carcinoma.

Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.

Patients with symptoms of cognitive impairment who practiced web-based memory and mental processing exercises over a period of 15 weeks experienced marked improvement in their cognitive function.

A subgroup analysis from a phase III, open-label, randomized study showed that eribulin had comparable activity to dacarbazine in patients with leiomyosarcoma.

Sundar Jagannath, MD, discusses the importance of the standardization of a 3-drug regimen for newly diagnosed multiple myeloma, how the regimen may evolve going forward, and other novel agents on the horizon.

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

Palbociclib demonstrated consistent improvement in progression-free survival when combined with endocrine therapy in patients with advanced estrogen receptor-positive breast cancer.

When envisioning the future treatment paradigms for myelodysplastic syndromes and acute myeloid leukemia, researchers predict that hypomethylating agents, immunotherapies, and multikinase and BCL-2 inhibitors are just a few examples of what the field can expect in the coming years.

A new drug application to the FDA has been completed for niraparib as a maintenance treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Results from the phase II CheckMate-275 trial demonstrated favorable safety and efficacy with the PD-1 inhibitor nivolumab as a second-line treatment for patients with metastatic urothelial cancer who have progressed on first-line chemotherapy.

Both myelofibrosis and polycythemia vera are myeloproliferative neoplasms with very specific characteristics and treatment strategies.

Surgery and radiation therapy are standard treatment options for localized prostate cancer, but are not comparative to one another.

The FDA granted a priority review to ribociclib for use in combination with letrozole as a frontline therapy for patients with hormone-receptor–positive, HER2-negative advanced breast cancer.

While immunotherapy is currently only beneficial in select cancers, it is possible for this type of treatment to eventually work for all patients.